Taken together, these findings may provide a likely explanation for the beneficial effects of GLP1-Ras observed in the overall metabolic abnormalities associated with MASLD and involved in its progression to MASH through the GLP1-FGF21-fetuin-A axis. Here, FGF21 is linked to metabolic dysfunction-associated steatotic liver disease.